SCHEMBL19956979

SCHEMBL19956979

COC(=O)c1cc2c(Oc3ccc(NC(=S)NC4CC4)c(Cl)c3)ccnc2cc1OC

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 10/20 0.72
KDR P35968 8/20 0.72
PDGFRA P16234 6/20 0.72
PDGFRB P09619 4/20 0.72
FGFR1 P11362 4/20 0.72
KIT P10721 4/20 0.72
AURKB Q96GD4 4/20 0.72
RET P07949 3/20 0.72
FLT1 P17948 3/20 0.72
FLT4 P35916 3/20 0.72
ABL1 P00519 3/20 0.72
FGFR2 P21802 2/20 0.72
FGFR3 P22607 2/20 0.72
RIPK2 O43353 2/20 0.72
STK10 O94804 2/20 0.72
BCR P11274 2/20 0.72
SLC6A3 Q01959 2/20 0.72
DDR1 Q08345 2/20 0.72
MAP4K2 Q12851 2/20 0.72
PTK6 Q13882 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19957046 0.94 KDR (0.73) FGFR4KDRPDGFRAPDGFRBFGFR1
SCHEMBL19957112 0.93 FGFR4 (0.72) FGFR4KDRPDGFRAPDGFRBFGFR1
SCHEMBL19956987 0.93 KDR (0.85) FGFR4KDRPDGFRAPDGFRBFGFR1
SCHEMBL19956955 0.93 KDR (0.71) FGFR4KDRPDGFRAPDGFRBFGFR1
SCHEMBL1894913 0.92 FGFR4 (0.86) FGFR4KDRPDGFRAPDGFRBFGFR1
SCHEMBL30083675 0.92 FGFR4 (0.86) FGFR4KDRPDGFRAPDGFRBFGFR1
SCHEMBL19957118 0.91 FGFR4 (0.69) FGFR4KDRPDGFRAPDGFRBFGFR1
SCHEMBL19956957 0.90 KDR (0.79) FGFR4KDRPDGFRAPDGFRBFGFR1
SCHEMBL19957208 0.89 FGFR4 (0.66) FGFR4KDRPDGFRAPDGFRBFGFR1
SCHEMBL19957158 0.89 FGFR4 (0.67) FGFR4KDRPDGFRAPDGFRBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 FGFR4 146/4885KDR 150/4885PDGFRA 127/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 FGFR4 146/4885KDR 150/4885PDGFRA 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.